Lisdexamfetamine Dimesylate Patent Expiration
Lisdexamfetamine Dimesylate is Used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children. It was first introduced by Takeda Pharmaceuticals Usa Inc
Lisdexamfetamine Dimesylate Patents
Given below is the list of patents protecting Lisdexamfetamine Dimesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vyvanse |
US7105486 (Pediatric) | Abuse-resistant amphetamine compounds |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7223735 (Pediatric) | Abuse resistant lysine amphetamine compounds |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7655630 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7659253 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7659254 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7662787 (Pediatric) | Abuse resistant lysine amphetamine compounds |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7662788 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7671030 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7671031 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7674774 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7678770 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7678771 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7687466 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7687467 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7700561 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7713936 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7718619 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse |
US7723305 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7105486 | Abuse-resistant amphetamine compounds |
Jun 29, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7223735 | Abuse resistant lysine amphetamine compounds |
Jun 29, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7700561 | Abuse-resistant amphetamine prodrugs |
Jun 29, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7687467 | Abuse-resistant amphetamine prodrugs |
Apr 08, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7678770 | Abuse-resistant amphetamine prodrugs |
Mar 25, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7678771 | Abuse-resistant amphetamine prodrugs |
Mar 25, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7674774 | Abuse-resistant amphetamine prodrugs |
Mar 18, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7671031 | Abuse-resistant amphetamine prodrugs |
Feb 28, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7105486 | Abuse-resistant amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7223735 | Abuse resistant lysine amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7655630 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7655630 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7659253 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7659253 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7659254 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7662787 | Abuse resistant lysine amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7662787 | Abuse resistant lysine amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7662788 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7671030 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7671031 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7674774 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7678770 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7678771 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7687466 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7687467 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7700561 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7713936 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7718619 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
| Vyvanse | US7723305 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lisdexamfetamine Dimesylate's patents.
Latest Legal Activities on Lisdexamfetamine Dimesylate's Patents
Given below is the list recent legal activities going on the following patents of Lisdexamfetamine Dimesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Oct, 2021 | US7718619(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Oct, 2021 | US7713936 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Oct, 2021 | US7723305(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Sep, 2021 | US7700561(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7674774(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7687466(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7678770(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7671031(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7671030(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7678771(Litigated) |
Lisdexamfetamine Dimesylate's Family Patents
Explore Our Curated Drug Screens
Lisdexamfetamine Dimesylate Generic API Manufacturers
Several generic applications have been filed for Lisdexamfetamine Dimesylate. The first generic version for Lisdexamfetamine Dimesylate was by Hikma Pharmaceuticals Usa Inc and was approved on Aug 25, 2023. And the latest generic version is by Sandoz Inc and was approved on Jul 26, 2024.
Given below is the list of companies who have filed for Lisdexamfetamine Dimesylate generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS ELIZABETH
Actavis Elizabeth Llc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Actavis Elizabeth.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
Manufacturing Plant Locations New
Actavis Elizabeth's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Actavis Elizabeth as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
2. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
3. AMNEAL
Amneal Pharmaceuticals Llc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
4. APOTEX
Apotex Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
5. ASCENT PHARMS INC
Ascent Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Ascent Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
6. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 10MG | capsule | Prescription | ORAL | AB | Jan 17, 2024 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
7. LANNETT CO INC
Lannett Co Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
8. MSN
Msn Laboratories Private Ltd has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG | tablet, chewable | Prescription | ORAL | AB | Feb 2, 2024 |
| 60MG | tablet, chewable | Prescription | ORAL | AB | Feb 2, 2024 |
| 10MG | tablet, chewable | Prescription | ORAL | AB | Feb 2, 2024 |
| 20MG | tablet, chewable | Prescription | ORAL | AB | Feb 2, 2024 |
| 30MG | tablet, chewable | Prescription | ORAL | AB | Feb 2, 2024 |
| 40MG | tablet, chewable | Prescription | ORAL | AB | Feb 2, 2024 |
Manufacturing Plant Locations New
Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||
| United States |
| |||||||||||||||||||||
9. MYLAN
Mylan Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
10. NORWICH
Norwich Pharmaceuticals Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Norwich.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
Manufacturing Plant Locations New
Norwich's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Norwich as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
11. PRINSTON INC
Prinston Pharmaceutical Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Prinston Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
12. RHODES PHARMS
Rhodes Pharmaceuticals Lp has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Rhodes Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
13. SANDOZ
Sandoz Inc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | capsule | Discontinued | ORAL | N/A | Jul 26, 2024 |
| 50MG | capsule | Discontinued | ORAL | N/A | Jul 26, 2024 |
| 40MG | capsule | Discontinued | ORAL | N/A | Jul 26, 2024 |
| 30MG | capsule | Discontinued | ORAL | N/A | Jul 26, 2024 |
| 20MG | capsule | Discontinued | ORAL | N/A | Jul 26, 2024 |
| 70MG | capsule | Discontinued | ORAL | N/A | Jul 26, 2024 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
14. SPECGX LLC
Specgx Llc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Specgx Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
Manufacturing Plant Locations New
Specgx Llc's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Specgx Llc as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||
15. SUN PHARM INDS INC
Sun Pharmaceutical Industries Inc has filed for 7 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
| 70MG | capsule | Prescription | ORAL | AB | Aug 25, 2023 |
16. TEVA PHARMS
Teva Pharmaceuticals Development Inc has filed for 6 different strengths of generic version for Lisdexamfetamine Dimesylate. Given below are the details of the strengths of this generic introduced by Teva Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 10MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 20MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 30MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 40MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 50MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |
| 60MG | tablet, chewable | Prescription | ORAL | AB | Aug 25, 2023 |